// App-Quantinova.ai

OT2-08-02 : Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290)

Researchers

Presenter

  • Peter Schmid

Principal Investigators

  • Javier Cortes

  • Mark Robson

  • Hiroji Iwata

  • Roberto Hegg

  • Sunil Verma

  • Marina Nechaeva

  • Binghe Xu

  • Vincent Haddad

  • Esteban Rodrigo Imedio

  • Gaia Schiavon

  • Andrew Foxley

  • Yeon Hee Park

Medical Centers

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • IOB, Institute of Oncology, QuironSalud Group, Barcelona, Spain

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • Clínica de Pesquisa e Centro de Estudos em Oncologia Ginecológica e Mamária, São Paulo, Brazil

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • Arkhangelsk Regional Clinical Oncologic Dispensary, Arkhangelsk, Russia

  • 4National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen, China

  • Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom

  • Kyung Hee Medical Center Seoul Korea, Republic of

Locations

  • United Kingdom

  • Spain

  • United States

  • Japan

  • Brazil

  • Canada

  • Russia

  • China

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Paclitaxel

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT02423603

  • NCT03997123

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved